Chinese API supplier under FDA scrutiny
October 3, 2011Manufacturing and Production Sichuan Pharmaceutical, pharma manufacturing news
Chinese active ingredient manufacturer Sichuan Pharmaceutical has been sent a warning by the US FDA for failing to sort out …
Janssen repeats digital award success
September 30, 2011Medical Communications PM Society Digital Awards
Janssen was once again the standout winner at last night’s PM Society’s Digital Media Awards. The pharma company beat its …
NICE says no to lupus treatment
September 30, 2011Sales and Marketing Benylsta, GSK, Lupus, NICE
NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …
Chiltern expands North American Operation with a new office in Illinois
September 30, 2011Research and Development
Mr. Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint …
Astellas abandons oral anticoagulant darexaban
September 30, 2011Research and Development Astellas, Eliquis, Xarelto, darexaban
Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
NICE refuses to back Sanofi’s Jevtana
September 30, 2011Sales and Marketing Jevtana, NICE
NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …
R&D jobs in emerging markets – leaders wanted
September 29, 2011Business Services, Research and Development Jobs, careers, pharma jobs
The globalisation of pharmaceutical research and development is creating a wave of job opportunities in emerging markets such as India …
Merck pulls out of J&J consumer venture
September 29, 2011Sales and Marketing J&J, JJ, Merc & Co, OTC
Merck & Co has exited a joint venture with J&J, selling its stake in the J&J/Merck Consumer Pharmaceuticals business to …
NICE blames pharma R&D model for spiralling cancer drug costs
September 29, 2011Research and Development, Sales and Marketing Cancer, NICE, clincial trials
NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …
Novartis’ brain tumour drug Votubia launched in UK
September 29, 2011Sales and Marketing Afinitor, Votubia
Novartis has launched its orphan drug Votubia in the UK for patients with a rare type of brain tumour. Votubia …
Commissioning groups want more support and less red tape
September 29, 2011NHS reforms
Clinical Commissioning Groups are concerned by the amount of bureaucracy they face and feel they don’t have enough support, according …
Researchers call for European clinical trial reform
September 28, 2011Research and Development Euorpe, clinical trials
Medical researchers are calling for regulatory red tape to be snipped away from the legal requirements around clinical trials in …
Gardasil better value for money than Cervarix, finds new study
September 28, 2011Sales and Marketing Cervarix, Gardasil, HPV, cervical cancer
A new report by the Health Protection Agency has found that Gardasil is a more cost-effective vaccine for cervical cancer …
Lilly launches ‘open innovation’ drug discovery
September 28, 2011Research and Development OIDD, TB, lilly
Lilly has launched a new open innovation platform designed to help build its pipeline and to identify new treatments for …
SHL to speak at the upcoming Drug Delivery Trends symposium in Korea
September 28, 2011Manufacturing and Production auto injector, autoinjector, drugy delivery, pharmapack
SHL Marketing Director Steven Kaufman will be speaking at the upcoming Primary Packaging and Drug Delivery Trends for Injectables symposium …
Cancer costs on an ‘unaffordable trajectory’
September 28, 2011Sales and Marketing Cancer, healthcare costs
The cost of cancer is rising too fast with new treatments giving uncertain benefits, according to a new study. A …
Roche’s Herceptin successor impresses at EMCC
September 27, 2011Research and Development Herceptin, Roche, TDM-1
Roche’s next-generation breast cancer drug T-DM1 has impressed at the European cancer congress after besting Herceptin in a new study. …
Boehringer to create biosimilars division
September 27, 2011Research and Development Boehringer, biosimilars
Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that …
MTS Medication Technologies appoints Paul O’Hanlon
September 27, 2011Manufacturing and Production appointments, manufacturing and production
MTS Medication Technologies has appointed Paul O’Hanlon as managing director of its International Division. He has 27 years of experience …
Lonza signs regenerative medicine deal with Mesoblast
September 27, 2011Manufacturing and Production Lonza, Mesoblast, pharma manufacturing news
Lonza has entered into a strategic-level alliance with Mesoblast, a specialist in regenerative medicines, which could see the construction of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
